BIO-Europe
Vienna, Austria
3-5 November 2025
News
Events
Boston CEO Longwood Healthcare Leaders
Boston, USA
27-28 October 2025EORTC-NCI-AACR international conference on molecular targets and cancer therapeutics
Boston, USA
22-26 October 2025ESMO Congress
Berlin, Germany
17-21 October 2025
MODULATING DNA DAMAGE RESPONSES TO CURE CANCER
Breakpoint Therapeutics Announces Poster Presentation at the 36th EORTC-NCI-AACR Symposium
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it will present preclinical data from its polymerase theta (Pol θ / POLQ) inhibitor programme in a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024 in Barcelona, Spain (ENA 2024).
Breakpoint Therapeutics Announces Development Candidate Nomination and Start of IND-Enabling Activities of Potential Best-in-Class Polymerase Theta (Pol θ / POLQ) Inhibitor
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ) with best-in-class potential, for the treatment of solid tumours. IND-enabling activities have already commenced.
Breakpoint To Chair and Present at DDR Inhibitors Summit 2024
Breakpoint’s Managing Directors Daniel Speidel and Jon Hollick will attend the DDR Inhibitors Summit 2024 in Boston (30 January- 1 February 2024). At this international meeting, experts from industry and academia gather to share and discuss updates in the development of novel therapeutics targeting the DNA Damage response in cancer cells. Daniel Speidel will chair […]